Trial reportNature medicine2024
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.
Abstract readClinical Trial, Phase IIClinical Trial, Phase IMulticenter Study
In one paragraph
Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.The lancet. HIV · 2026Trial
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- Trial
- Article
- Tissue origins and immune correlates of viral rebound in SIV-infected rhesus macaques after ART discontinuation.Science translational medicine · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.Nature microbiology · 2026Article
- Proof-of-Concept Development and Preclinical Evaluation of a Microarray Patch Platform for Codelivery of Multiple Broadly Neutralizing Antibodies for HIV Prevention.Molecular pharmaceutics · 2026Article
- Haplotype and diversity signatures of ultra-soft selective sweeps in HIV-1.bioRxiv : the preprint server for biology · 2026Article
- Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.iScience · 2026Article
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control.bioRxiv : the preprint server for biology · 2026Article
- Review
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- Clinical Pharmacology Quality Assurance Program for Global HIV and Co-Infection Drug Development.Clinical pharmacology and therapeutics · 2026Review
- Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment.Tropical medicine and infectious disease · 2026Review
- Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail.Toxins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Boris Julg *Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. bjulg@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-4687-9626
Victoria E K Walker-Sperling *Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7847-7931
Kshitij Wagh *Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0001-7552-6582
Malika AidCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4498-7893
Kathryn E StephensonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3440-4105
Rebecca ZashCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jinyan LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Joseph P NkololaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Amelia HoytCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1307-2508
Mike CastroVaccine Research Center, National Institute of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-8045-1754
Leonid SerebryannyyVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
Katherine YanosickCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Tessa SpeidelCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Erica N BorducchiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Tetyana MurzdaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1800-1784
Lori MaxfieldCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7595-6205
Roberto ArduinoHouston AIDS Research Team, McGovern Medical School at The University of Texas Health Science Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7381-844X
Adrian B McDermottVaccine Research Center, National Institute of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0616-9117
Lucio GamaVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
Elena E GiorgiTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
Richard A KoupVaccine Research Center, National Institute of Health, Bethesda, MD, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Charlotte-Paige RolleOrlando Immunology Center, Orlando, FL, USA.
Edwin DeJesusOrlando Immunology Center, Orlando, FL, USA.
Wenjun LiUniversity of Massachusetts, Lowell, MA, USA.ORCID http://orcid.org/0000-0001-5335-7386
Bette KorberTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-2026-5757
Dan H BarouchRagon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. dbarouch@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-5127-4659
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ALTER, GALIT · 2018 to 2022
$14.0MUnderstanding reservoir dynamics through analysis of viral decay processesP01AI169615 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ALAN S PERELSON · 2022 to 2026
$9.5MAd26 Based Therapeutic Vaccines for HIVU01AI145801 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., JUELG, BORIS DOMINIK · 2020 to 2025
$9.0MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MNHP CoreP01AI177687 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch · 2023 to 2026
$7.4MOptimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9MSingle-Cell Analysis of the HIV/SIV ReservoirR01AI149670 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., SHALEK, ALEX K · 2020 to 2024
$4.6MVaccine induced T-cell protection against SIV infectionK08AI106408 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2013 to 2017
$938kDiversity of Immune Responses Elicited by HIV VaccinesK23AI114381 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STEPHENSON, KATHRYN ELAINE · 2014 to 2018
$818kNCATS NIH HHS UL1 TR001102NIAID NIH HHS K08 AI106408NIAID NIH HHS K23 AI114381NIAID NIH HHS P01 AI169615NIAID NIH HHS P01 AI177687NIAID NIH HHS R01 AI149670NIAID NIH HHS R37 AI150590NIAID NIH HHS T32 AI007387NIAID NIH HHS U01 AI145801NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI164556U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI124377, AI128751, AI145801, AI149670, AI164556, AI169615, AI177687
Abstract
Human immunodeficiency virus type 1 (HIV-1)-specific broadly neutralizing monoclonal antibodies (bNAbs) have to date shown transient viral suppression when administered as monotherapy or as a cocktail of two antibodies
Indexed as
Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsAdultAntibodies, MonoclonalBroadly Neutralizing AntibodiesCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedViral LoadAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.